Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04315233 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Study acronym: CHARGE
StatusTerminated
PhasePhase 1
Started2021-05-03
View on ClinicalTrials.gov ↗
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.

Amendment history 5 changes detected by DataLookout

2026-09-05
Trial terminated: No accrual in one year
2026-09-05
Primary endpoint(s) modified
WasMTD of ribociclib and belinostat combination
NowRate of Dose Limiting Toxicity (DLT)
2026-09-05
Final enrollment: 12 participants (planned 34)
2026-09-05
Primary completion confirmed: March 2024 (last estimated June 2025)
2026-09-05
Results posted: 2026-09-04
Trial Details
NCT Number NCT04315233
Lead Sponsor University of Utah
Collaborators: Novartis, Acrotech Biopharma, National Cancer Institute (NCI)
Conditions Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Enrollment 12 participants
Start Date 2021-05-03
Primary Completion 2024-03-14 (estimated)
Study Completion 2025-09-25 (estimated)
Updated on ClinicalTrials.gov 2026-09-04